切换至 "中华医学电子期刊资源库"

中华肝脏外科手术学电子杂志 ›› 2013, Vol. 02 ›› Issue (06) : 367 -370. doi: 10.3877/cma.j.issn.2095-3232.2013.06.005

所属专题: 文献

临床研究

乙型病毒性肝炎后肝硬化患者的肝功能状况对顺阿曲库铵肌松效应的影响
黎尚荣1,(), 黄菲1, 罗刚健1   
  1. 1. 510630 广州,中山大学附属第三医院麻醉科
  • 收稿日期:2013-08-19 出版日期:2013-12-10
  • 通信作者: 黎尚荣
  • 基金资助:
    广东省科技计划项目(2010B080701084)

Impact of liver function on muscle-relaxant effect of cisatracurium in patients with hepatitis B cirrhosis

Shang-rong LI1,(), Fei HUANG1, Gang-jian LUO1   

  1. 1. Department of Anesthesiology, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China
  • Received:2013-08-19 Published:2013-12-10
  • Corresponding author: Shang-rong LI
  • About author:
    Corresponding author: LI Shang-rong, Email:
引用本文:

黎尚荣, 黄菲, 罗刚健. 乙型病毒性肝炎后肝硬化患者的肝功能状况对顺阿曲库铵肌松效应的影响[J]. 中华肝脏外科手术学电子杂志, 2013, 02(06): 367-370.

Shang-rong LI, Fei HUANG, Gang-jian LUO. Impact of liver function on muscle-relaxant effect of cisatracurium in patients with hepatitis B cirrhosis[J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2013, 02(06): 367-370.

目的

探讨乙型病毒性肝炎(乙肝)后肝硬化患者的肝功能状况对顺阿曲库铵麻醉诱导过程中肌松效应的影响。

方法

回顾性分析2011年4月至2013年2月在中山大学附属第三医院麻醉科全身麻醉下行上腹部手术的55例乙肝后肝硬化患者临床资料。根据肝功能Child-Pugh分级将患者分为A级组(32例)和B级组(23例)。A级组男19例,女13例;年龄(43±8)岁。B级组男12例,女11例;年龄(45±8)岁。所有患者均签署知情同意书,符合医学伦理学规定。两组患者均给予咪达唑仑0.05 mg/kg、异丙酚1.5 mg/kg、芬太尼4 μg/kg和顺阿曲库铵0.15 mg/kg静脉注射进行麻醉诱导。采用TOF-Watch SX加速度肌松监测仪记录两组患者使用顺阿曲库铵后的肌松效应,包括肌松起效时间、4个成串刺激(TOF)无反应时期、25%TOF恢复时间、50%TOF恢复时间、75%TOF恢复时间、肌松恢复指数,并评估气管插管条件。两组计量资料的比较采用t检验,两组计数资料的比较采用χ2检验。

结果

两组患者气管插管条件均为优或良,差异无统计学意义(χ2=0.15,P>0.05)。与B级组比较,A级组的肌松起效时间、TOF无反应期、25%TOF恢复时间、50%TOF恢复时间和75%TOF恢复时间较短,A级组的肌松恢复指数较低,但差异均无统计学意义(t=1.24,1.04,0.97,1.96,1.41,1.34;P>0.05)。

结论

顺阿曲库铵应用于肝功能Child-Pugh分级为A级和B级的乙肝后肝硬化患者时,其气管插管条件与肌松效应均不受肝功能分级的影响,临床应用时无需调整剂量。

Objective

To investigate the impact of liver function on muscle-relaxant effect of cisatracurium in the anesthesia induction in patients with hepatitis B cirrhosis.

Methods

Clinical data of 55 patients with hepatitis B cirrhosis who received upper abdomen surgery under general anesthesia from April 2011 to February 2013 in Department of Anesthesiology, the Third Affiliated Hospital of Sun Yat-sen University were analyzed retrospectively. According to liver function Child-Pugh grade, the patients were divided into two groups: grade-A group [n=32; 19 males, 13 females; (43±8) years old], grade-B group [n=23; 12 males,11 females; (45±8) years old]. The informed consents of all patients were obtained and the ethical committee approval was received. Anesthesia was induced with intravenous midazolam (0.05 mg/kg), propofol (1.5 mg/kg), fentanyl (4 μg/kg) and cisatracurium (0.15 mg/kg) in patients of two groups. The muscle-relaxant effect in patients of two groups after use of cisatracurium, including the onset time of muscle relaxation, period of no-response to train-of-four stimulation (TOF), recovery time of 25%TOF, 50%TOF,75%TOF, and muscle relaxation recovery indexes were recorded by accelerating muscle relaxation monitor TOF-Watch SX, and the tracheal intubation condition was assessed. The measurement data were compared by t test and enumeration data were compared by Chi-square test.

Results

The tracheal intubation condition in patients of two groups were both excellent or good and no significant difference was observed between two groups (χ2=0.15; P>0.05). Compared with grade-B group, the onset time of muscle relaxation, period of no-response to TOF, recovery time of 25%TOF, 50%TOF, 75%TOF were shorter in grade-A group, whose muscle relaxation recovery indexes was lower. But there was no significant difference(t=1.24, 1.04, 0.97, 1.96, 1.41, 1.34; P>0.05).

Conclusions

The tracheal intubation condition and muscle-relaxant effect are not affected by liver function Child-Pugh grade when cisatracurium is administered in patients with hepatitis B cirrhosis of Child-Pugh grade-A or B. There is no need to adjust the dose when cisatracurium is used in clinic.

表1 两组不同肝功能乙型病毒性肝炎后肝硬化患者气管插管条件评价(例)
表2 两组不同肝功能乙型病毒性肝炎后肝硬化患者的肌松效应比较(min,±s
[1]
庄心良,曾因明,陈伯銮.现代麻醉学. 3版.北京:人民卫生出版社, 2004: 562-589.
[2]
Tran TV,Fiset P,Varin F. Pharmacokinetics and pharmacodynamics of cisatracurium after a short infusion in patients under propofol anesthesia. Anesth Analg, 1998, 87(5): 1158-1163.
[3]
Bergeron L,Bevan DR,Berrill A, et al. Concentration-effect relationship of cisatracurium at three different dose levels in the anesthetized patient. Anesthesiology, 2001, 95(2): 314-323.
[4]
Meretoja O. Update on muscle relaxants. Paediatr Anaesth, 2004, 14(5): 384-386.
[5]
邹宗强,孟凡民.顺式阿曲库铵用于肝硬化患者全凭静脉麻醉的肌松效应.山东医药, 2009, 49(16): 53-54.
[6]
殷国平,胡万进,张维峰,等.麻醉方法对肝炎肝硬化手术患者免疫功能的影响.江苏医药, 2013, 39(11): 1284-1286.
[7]
朱宇麟,景桂霞,赵鸽,等.顺苯磺酸阿曲库铵在肝移植患者应用中的肌松效果及安全性.广东医学, 2009, 30(4): 588-589.
[8]
崔春吉.终末期肝病模型在评估肝硬化患者预后中的价值.世界华人消化杂志, 2010, 18(22): 2375-2378.
[9]
Cooper R,Mirakhur RK,Clarke RS, et al. Comparison of intubating conditions after administration of Org 9246 (rocuronium) and suxamethonium. Br J Anaesth, 1992, 69(3): 269-273.
[10]
Benedeto-Stojanov D,Nagorni A,Bjelakovic G, et al. The model for the end-stage liver disease and Child-Pugh score in predicting prognosis in patients with liver cirrhosis and esophageal variceal bleeding. Vojnosanit Pregl, 2009, 66(9): 724-728.
[11]
李灵敏,肖天利,陈文生. MELD与CTP评分系统对TIPS术后患者预后的评价作用.第三军医大学学报, 2009, 31(8): 733-736.
[12]
Soubhia AF,Lauz S,Montero EF, et al. Effects of the inhalational anesthetics halothane and sevoflurane on an experimental model of hepatic injury. Rev Bras Anestesiol, 2011, 61(5): 324-330, 591-603.
[13]
Alotaibi WM. Severe hepatic dysfunction after sevoflurane exposure. Saudi Med J, 2008, 29(9): 1344-1346.
[14]
邬子林,佘守章,许立新,等.腹部手术中慢性肝功能不全病人罗库溴铵的药效学.中华麻醉学杂志, 2005, 25(9): 653-656.
[15]
周洁,齐波,王祥瑞,等.肝功能不全门脉高压病人罗库溴铵的肌松效应.中华麻醉学杂志, 2004, 24(8): 585-587.
[16]
Kisor DF,Schmith VD. Clinical pharmacokinetics of cisatracurium besilate. Clin Pharmacokinet, 1999, 36(1): 27-40.
[1] 李建美, 邓静娟, 杨倩. 两种术式联合治疗肝癌合并肝硬化门静脉高压的安全性及随访评价[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 41-44.
[2] 吴方园, 孙霞, 林昌锋, 张震生. HBV相关肝硬化合并急性上消化道出血的危险因素分析[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 45-47.
[3] 莫闲, 杨闯. 肝硬化患者并发门静脉血栓危险因素的Meta分析[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 678-683.
[4] 雷雪雪, 于颖, 李虹彦. 乙型肝炎肝硬化患者肝移植等待期应用多模式预康复优化项目的临床研究[J]. 中华移植杂志(电子版), 2023, 17(03): 158-163.
[5] 李芳, 孙海云. 风险因素护理干预对合并失代偿性肝硬化的腹股沟疝患者Lichtenstein术围手术期应用效果[J]. 中华疝和腹壁外科杂志(电子版), 2023, 17(04): 477-480.
[6] 韩宇, 张武, 李安琪, 陈文颖, 谢斯栋. MRI肝脏影像报告和数据系统对非肝硬化乙肝患者肝细胞癌的诊断价值[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 669-673.
[7] 李勇, 兰川, 吴斌, 张光年, 李敬东. 术前血小板-白蛋白评分对肝硬化肝癌术后预后的预测价值[J]. 中华肝脏外科手术学电子杂志, 2023, 12(04): 412-416.
[8] 许语阳, 吕云福, 王葆春. 乙肝后肝硬化门静脉高压症脾肿大外科治疗进展[J]. 中华肝脏外科手术学电子杂志, 2023, 12(04): 469-473.
[9] 杨林青, 任松, 纪泛扑, 张健, 蒋安, 张丽, 安鹏, 王林, 李宗芳. 揿针疗法对门静脉高压症脾切除断流术后胃肠功能的调节作用[J]. 中华肝脏外科手术学电子杂志, 2023, 12(03): 322-326.
[10] 秦维, 王丹, 孙玉, 霍玉玲, 祝素平, 郑艳丽, 薛瑞. 血清层粘连蛋白、Ⅳ型胶原蛋白对代偿期肝硬化食管胃静脉曲张出血的预测价值[J]. 中华消化病与影像杂志(电子版), 2023, 13(06): 447-451.
[11] 张雯, 宋牡丹, 邓雪婷, 张云. 强化营养支持辅助奥曲肽治疗肝硬化合并食管胃底静脉曲张破裂出血的疗效及再出血危险因素[J]. 中华消化病与影像杂志(电子版), 2023, 13(06): 456-460.
[12] 朱翔宇, 王建美, 张辉, 叶红英. 无创左心室压力-应变循环技术在左心室功能参数与肝硬化的相关性分析[J]. 中华消化病与影像杂志(电子版), 2023, 13(06): 494-498.
[13] 郭亮亮, 邱珊珊, 钟萍, 赵心恺. 血小板-白蛋白-胆红素评分对肝硬化上消化道出血的诊断价值[J]. 中华消化病与影像杂志(电子版), 2023, 13(04): 216-219.
[14] 朱风尚, 舍玲, 丁永年, 杨长青. 五步疑问法在肝硬化门静脉高压症临床教学中的应用[J]. 中华消化病与影像杂志(电子版), 2023, 13(02): 116-118.
[15] 孔凡彪, 杨建荣. 肝脏基础疾病与结直肠癌肝转移之间关系的研究进展[J]. 中华临床医师杂志(电子版), 2023, 17(07): 818-822.
阅读次数
全文


摘要